Consistent with a recent analysis of GBM’s molecular profile and specific immunological markers, which revealed higher expression of CD8 and CD68 in GBM cases with an unmethylated MGMT promoter compared to the methylated counterpart (9), our comprehensive genetic analysis consistently demonstrated enhanced immune responses in GBM with MGMT-H tumors. Here, CD8A is linked to glioblastoma.